Ghost Tree Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Ghost Tree Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-200,000	Closed	-$2.37M	–	75
2024 Q1	$2.37M	Buy	200,000 +69,964	+54%	+$933K	0.66%	50
2023 Q4	$1.59M	Buy	130,036 +30,036	+30%	+$273K	0.52%	43
2023 Q3	$963K	Buy	+100,000	New	+$1.02M	0.32%	59
2021 Q1	–	Sell	-200,000	Closed	-$3.8M	–	52
2020 Q4	$3.8M	Sell	200,000 -150,000	-43%	-$2.57M	0.85%	32
2020 Q3	$4.41M	Hold	350,000	–	–	1.27%	26
2020 Q2	$4.24M	Hold	350,000	–	–	1.12%	30
2020 Q1	$2.68M	Sell	350,000 -65,000	-16%	-$877K	0.71%	31
2019 Q4	$7.39M	Buy	415,000 +100,000	+32%	+$1.31M	1.41%	27
2019 Q3	$3.65M	Buy	315,000 +15,000	+5%	+$242K	0.93%	34
2019 Q2	$6.64M	Sell	300,000 -100,000	-25%	-$2.35M	1.38%	20
2019 Q1	$11.4M	Sell	400,000 -25,000	-6%	-$542K	2.99%	11
2018 Q4	$8.39M	Buy	425,000 +200,000	+89%	+$4.02M	3.05%	12
2018 Q3	$4.97M	Buy	+225,000	New	+$3.04M	1.06%	31

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ghost Tree Capital's KALV Position: Q2 2024 in Review

Ghost Tree Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2024, closing a stake of 200,000 shares — an estimated $2.37M sold.

Ghost Tree Capital first reported a position in KALV in Q3 2018 and held it in 13 quarters. The position peaked at $11.4M in Q1 2019. 119 funds tracked by Wall St. Rank hold KALV as of Q2 2024.

Ghost Tree Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Ghost Tree Capital sold 200,000 KalVista Pharmaceuticals shares in Q2 2024, an estimated $2.37M.
Ghost Tree Capital first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 13 quarters.
Ghost Tree Capital's KalVista Pharmaceuticals position peaked at $11.4M in Q1 2019.
119 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2024.

Based on Ghost Tree Capital's 13F filing for Q2 2024, filed 14 Aug 2024.